Trial Profile
A prospective study evaluating omalizumab for symptom control in patients with chronic rhinosinusitis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Mar 2017
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Rhinosinusitis
- Focus Therapeutic Use
- 22 Mar 2017 New trial record
- 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology